Profile
Sebastian Inger has a current job as a Director at NBCD A.
Sebastian Inger active positions
Companies | Position | Start |
---|---|---|
NBCD A/S
NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
NBCD A/S
NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | Health Technology |
- Stock Market
- Insiders
- Sebastian Inger